An expert panel recommended approval of Novartis's experimental chimeric antigen 
T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or 
refractory B-cell acute lymphoblastic leukemia. The therapy would be the first 
of its kind approved for cancer and has the potential to transform standard of 
care for advanced blood cancers.